Detalhe da pesquisa
1.
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634143
2.
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am J Hematol
; 99(4): 615-624, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343151
3.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med
; 383(7): 617-629, 2020 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32786187
4.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
5.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 108(3): 705-716, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226495
6.
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Am J Hematol
; 98(8): 1254-1264, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334852
7.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Jpn J Clin Oncol
; 52(1): 29-38, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739075
8.
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.
J Oncol Pharm Pract
; 28(4): 892-897, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191732
9.
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 26(2): 300-306, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31550496
10.
How I treat FLT3-mutated AML.
Blood
; 129(5): 565-571, 2017 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872057
11.
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Am J Hematol
; 94(1): 111-117, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30370956
12.
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Lancet Oncol
; 19(2): 216-228, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29339097
13.
Azacitidine and Venetoclax in AML. Reply.
N Engl J Med
; 383(21): 2088-2089, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207106
14.
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
Blood
; 127(22): 2711-22, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26917778
15.
Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Am J Hematol
; 93(2): 213-221, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29139135
16.
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
Blood
; 125(19): 3024-31, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814532
17.
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
Haematologica
; 102(2): 391-400, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27846611
18.
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia.
J Natl Compr Canc Netw
; 15(7): 959-966, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28687582
19.
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
Am J Hematol
; 97(11): E422-E425, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053878
20.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Am J Hematol
; 97(11): E416-E419, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054316